Clinical Trials Logo

Congenital Bleeding Disorder clinical trials

View clinical trials related to Congenital Bleeding Disorder.

Filter by:

NCT ID: NCT00571584 Completed - Clinical trials for Congenital Bleeding Disorder

High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors

Start date: November 2002
Phase: Phase 4
Study type: Interventional

This trial is conducted in Europe. The aim of this trial is to evaluate the efficacy and safety of two dose schedules of activated recombinant human factor VII in treatment of joint bleeds in haemophilia patients with inhibitors.

NCT ID: NCT00486278 Completed - Clinical trials for Congenital Bleeding Disorder

Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds

Start date: June 2007
Phase: Phase 2
Study type: Interventional

This trial is conducted in Africa, Asia, Europe, Japan, and North and South America. The aim of this trial is to evaluate the safety and efficacy of activated recombinant human factor VII analogue (vatreptocog alfa (activated)) in haemophilia patients with inhibitors.

NCT ID: NCT00108797 Completed - Clinical trials for Congenital Bleeding Disorder

Trial of NovoSeven® in Haemophilia - Joint Bleeds

Start date: September 2001
Phase: Phase 4
Study type: Interventional

This trial is conducted in the United States of America (USA). This study compares the effectiveness and safety of NovoSeven® to FEIBA (FEIBA VH) in haemophilia patients with inhibitors being treated for joint bleeds.

NCT ID: NCT00108758 Completed - Clinical trials for Congenital Bleeding Disorder

Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia

Start date: March 2004
Phase: Phase 2
Study type: Interventional

This trial is conducted in Africa, Asia, Europe, South America, and the United States of America (USA). The purpose of this study is to evaluate the effectiveness of secondary prophylactic treatment with NovoSeven® in haemophilia A and B patients with inhibitors.

NCT ID: NCT00104455 Completed - Healthy Clinical Trials

Dose Response to Recombinant Factor VIIa When Administered for Bleed

Start date: June 2004
Phase: Phase 1
Study type: Interventional

This trial is conducted in the United States of America (USA). The purpose of this trial is to investigate the dose response to recombinant factor VIIa in healthy volunteers when administered for bleed.

NCT ID: NCT00056589 Completed - Clinical trials for Congenital Bleeding Disorder

Safety and Pharmacokinetics of Recombinant Factor XIII in Patients With Congenital Factor Xlll Deficiency

Start date: March 2003
Phase: Phase 1
Study type: Interventional

This trial was conducted in the United States of America (USA). The aim of this trial was to investigate safety and pharmacokinetics of escalating single doses of catridecacog (recombinant factor XIII, rFXIII) in patients with congenital factor XIII deficiency.